Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Denny

Showing results (11-20 of 748) with videos related to

Pageof 75
Sort By:
European Journal of Medicinal Chemistry|October 16, 2001
Prodrug strategies in cancer therapyW A Denny
Farmaco (Societa Chimica Italiana : 1989)|May 12, 2001
The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinasesW A Denny
Idrugs : the Investigational Drugs Journal|April 2, 2004
EdotecarinWilliam A Denny
Expert Opinion on Therapeutic Patents|March 16, 2013
Phosphoinositide 3-kinase α inhibitors: a patent reviewWilliam A Denny
Drug Design and Delivery|July 1, 1988
New directions in the design and evaluation of anti-cancer drugsW A Denny
Current Cancer Drug Targets|February 16, 2022
Inhibitors and Activators of the p38 Mitogen-Activated MAP Kinase (MAPK) Family as Drugs to Treat Cancer and InflammationWilliam A Denny
Oncology (Williston Park, N.Y.)|May 17, 2015
Questions we should be asking about bevacizumab for cervical cancerLynette A Denny
Expert Opinion on Emerging Drugs|May 25, 2004
Emerging DNA topisomerase inhibitors as anticancer drugsWilliam A Denny
Idrugs : the Investigational Drugs Journal|August 30, 2005
Inhibitors of receptor protein kinasesW A Denny
Current Medicinal Chemistry|April 3, 2001
DNA minor groove alkylating agentsW A Denny
Pageof 75

Showing results (11-20 of 748) with videos related to

Sort By:
Pageof 75
European Journal of Medicinal Chemistry|October 16, 2001
Prodrug strategies in cancer therapyW A Denny
Farmaco (Societa Chimica Italiana : 1989)|May 12, 2001
The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinasesW A Denny
Idrugs : the Investigational Drugs Journal|April 2, 2004
EdotecarinWilliam A Denny
Expert Opinion on Therapeutic Patents|March 16, 2013
Phosphoinositide 3-kinase α inhibitors: a patent reviewWilliam A Denny
Drug Design and Delivery|July 1, 1988
New directions in the design and evaluation of anti-cancer drugsW A Denny
Current Cancer Drug Targets|February 16, 2022
Inhibitors and Activators of the p38 Mitogen-Activated MAP Kinase (MAPK) Family as Drugs to Treat Cancer and InflammationWilliam A Denny
Oncology (Williston Park, N.Y.)|May 17, 2015
Questions we should be asking about bevacizumab for cervical cancerLynette A Denny
Expert Opinion on Emerging Drugs|May 25, 2004
Emerging DNA topisomerase inhibitors as anticancer drugsWilliam A Denny
Idrugs : the Investigational Drugs Journal|August 30, 2005
Inhibitors of receptor protein kinasesW A Denny
Current Medicinal Chemistry|April 3, 2001
DNA minor groove alkylating agentsW A Denny
Pageof 75